DaVita healthCare Partners Inc Stock News

Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.

Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.

Novo Nordisk shares rallied after it announced it will stop its FLOW trial nearly a year earlier than expected after positive feedback on interim data for semaglutide's ability to treat kidney disease

Ozempic may find yet another clinical use. The drug, developed by Danish pharmaceutical giant Novo Nordisk (NYSE: NVO ), has been making waves throughout the healthcare industry.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.

Novo Nordisk's Ozempic already is poised to disrupt a range of industries via its weight-loss benefits. Now it threatens companies which treat kidney failure.

DaVita Inc. stock has been heavily sold in '23, trading below its 50-day moving average for the past 8 weeks. The company lacks economic value, and its reinvestment runway looks limited, producing sub

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either DaVita HealthCare (DVA) or Chemed (CHE). But which of these two stocks offers value in

Stocks have faced pressure over the last several weeks, with continued uncertainty surrounding the economy weighing on investors' minds.

Investors target stocks that have been on a bullish run lately. Stocks like GIII, CEG, CWCO and DVA that are seeing price strength have a high chance of carrying the momentum forward.

Here is how DaVita HealthCare (DVA) and McKesson (MCK) have performed compared to their sector so far this year.

DHI, DVA, KMTUY, ELAN and BWMX have been added to the Zacks Rank #1 (Strong Buy) List on September 19, 2023.

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with DaVita HealthCare (DVA) and Chemed (CHE). But which of these two stocks offers value investors a better